Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus SOX versus placebo plus SOX for perioperative treatment of resectable gastric or gastroesophageal junction adenocarcinoma
CTR20261300Phase 3Active
- Sponsor
- Chengdu Shengdi
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Chengdu Shengdi. Started Apr 2026; status: active.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20261300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261300.